在治疗轻链心脏粉样化症的进展
Giuseppe Palmiero1, Paolo Milani2, Federica Verrillo1
1Department of Translational Medical Sciences, Inherited and Rare Cardiovascular Diseases Unit, University of Campania "Luigi Vanvitelli", Naples, Italy; European Reference Network for Rare Low Prevalence and Complex Diseases of the Heart-ERN GUARD Heart, Via P. Valdoni 7, Trieste 34100, Italy.
Heart failure clinics
|March 13, 2025
概括
系统性轻链氨基粉症 (AL) 是由于蛋白质产生异常而引起的,通常会影响心脏并导致器官损伤. 早期诊断和治疗对于改善患者的生存和治疗结果至关重要.
科学领域:
- 血液学 血液学 血液学
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 系统性轻链 (AL) 氨基粉症起源于血细胞或B细胞恶性瘤的异常免疫球蛋白轻链产生.
- 这种情况可以局部或全身表现,全身形式带有相当大的死亡风险,特别是当心脏参与时.
- 非特异性症状常常会延迟诊断,导致器官功能障碍逐渐恶化,生存率降低.
研究的目的:
- 提供对最近治疗AL心脏粉样化症的治疗进展的彻底审查.
- 突出早期识别和干预在治疗AL粉样性粉症方面的重要性.
- 总结目前的治疗策略,旨在抑制粉样蛋白的产生和减轻器官损伤.
主要方法:
- 最近临床试验和治疗发展的文献综述.
- 对AL心脏粉样化症的治疗结果和生存数据的分析.
- 综合了针对粉胺基因轻链的新型医学疗法的信息.
主要成果:
- 医学治疗的最新进展表明,在治疗AL心脏粉样性粉症方面有前途.
- 有效的治疗策略集中在抑制潜在的血细胞克隆和减少轻链生产.
- 早期和准确的诊断显著影响治疗疗效和患者的预后.
结论:
- 及时诊断和积极的治疗对于改善AL心脏 Amyloidosis的结果至关重要.
- 新型疗法为患者提供了新的希望,强调了持续研究和临床调查的必要性.
- 抑制amyloidogenic轻链生产是有效的AL心脏 Amyloidosis 管理的基石.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:26Heart Failure Drugs: Inotropic Agents
481
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
481
01:22Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141